Vanda Pharmaceuticals earnings were -$220.5M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest VNDA earnings report on Dec 31, 2025 announced Q4 2025 earnings of -$141.2M, up 525.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VNDA reported annual earnings of -$220.5M, with 1,066.5% growth.
Vanda Pharmaceuticals Earnings Reports & History FAQ
What were Vanda Pharmaceuticals's earnings last quarter?
On VNDA's earnings call on Invalid Date, Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 2025 earnings per share (EPS) of -$2.39, up 2,555.56% year over year. Total VNDA earnings for the quarter were -$141.19 million. In the same quarter last year, Vanda Pharmaceuticals's earnings per share (EPS) was -$0.09.
Is Vanda Pharmaceuticals profitable or losing money?
As of the last Vanda Pharmaceuticals earnings report, Vanda Pharmaceuticals is currently losing money. Vanda Pharmaceuticals's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$220.47 million, a 1,066.53% increase year over year.
What was VNDA's earnings growth in the past year?
As of Vanda Pharmaceuticals's earnings date in Invalid Date, Vanda Pharmaceuticals's earnings has grown year over year. VNDA earnings in the past year totalled -$220.47 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.